Moshe Ben-Shoshan

Featured in: Favicon

jamanetwork.com Favicon

unirioja.es Favicon

jacionline.org Favicon

annallergy.org Favicon

onlinelibrary.wiley.com Favicon

academic.oup.com + 1 more

Articles

Prevalence of omalizumab resistant chronic urticaria and real world effectiveness of dupilumab in omalizumab refractory chronic urticaria patients: a single center experience

May 9, 2024 | academic.oup.com | Moshe Ben-Shoshan

Chronic urticaria (CU) is characterized by wheals, angioedema, or both lasting for ≥ 6 weeks with chronic spontaneous urticaria (CSU) being the most common subtype. Omalizumab-resistant CSU cases represent an unmet clinical need. In this study, we aimed to assess the prevalence and predictors of omalizumab failure in a large cohort of CU patients and assess the effectiveness of dupilumab for omalizumab-recalcitrant CU. Of 338 CU patients, 33 received omalizumab.
Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)

Feb 3, 2023 | jacionline.org | Marcus Maurer |Charité-Universitätsmedizin Berlin |Thomas Casale |Moshe Ben-Shoshan

Mental Health Concerns of Patients And Their Caregivers In The FARE (Food Allergy Research & Education) Patient Registry Add To The Burden Of Food Allergy

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →